28.06.2018 • NewsElaine BurridgeValspar

US SEC Charges S&P Analyst on Insider Trading

US SEC Charges S&P Analyst on Insider Trading (c) Don Nichols/Getty Images
US SEC Charges S&P Analyst on Insider Trading (c) Don Nichols/Getty Images

The US Securities and Exchange Commission (SEC) has charged an analyst with credit ratings agency Standard & Poor’s (S&P) and two of his friends with insider trading related to last year’s merger between paint firms Sherwin-Williams and Valspar.

Sherwin-Williams bought Valspar in a deal valued at $11.3 billion in June 2017.

In the lawsuit, filed in Manhattan, SEC alleges that Sebastian Pinto-Thomaz, an S&P analyst based in New York, learned of the proposed acquisition when Sherwin Williams consulted the agency about the deal’s potential affect on its credit rating.

The SEC said that Pinto-Thomaz tipped off his friends – Abell Oujaddou, a co-owner of an upmarket New York hair salon and Jeremy Millul, a New York jeweler – who bought Valspar shares and options before the merger was announced, then sold them afterward, making a profit of around $192,000 and $107,000 respectively.

In a parallel action, the US Attorney’s Office for the Southern District of New York has announced criminal charges against the three.

S&P told Reuters news agency that Pinto-Thomaz has been suspended and that it is cooperating with authorities.

 

 

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.